



Background

Pyoderma gangrenosum (PG) is a non-healing, ulcerative skin disorder first described in 1930. It is a challenging disease to treat because of both diagnosis and treatment. However, familiarity with this disease may help increase the ability to treat patients.

Etiology

The etiology of PG is generally unknown. There is no clear link between PG and any demonstrated abnormalities in metabolic function. Proposed theories include: Subtypes of autoimmune process, resulting in abnormal migration of neutrophils; Intracellular metabolic dysfunction resulting in abnormal tracking of neutrophils; Drug-induced PG described, due to insulin, bromide, bromazepam, colony-stimulating factors, propylthiouracil, and alpha-2 agonists.

Characteristics and Clinical Appearance

Demonstrates pathologic phenomena (areas of skin ulcers) Typically begins as discrete pustule or pustules surrounded by erythema May have been infectious, traumatic, and neoplastic Pustule breaks down into deep, red or purple ulcer Center of ulcer is heaped up, and may be covered by hemorrhagic fibrin Can be ulcer or may be ulcer on 50-75% of cases associated with an underlying disease (See Table 1) Four types of PG have been described: Typical PG (most common) Acute PG (found more commonly in patients with hematologic disease) Atypical PG (found on back, palm, heel) Necrotizing PG (found on hand or neck, may have rheumatologic signs from underlying disease) Pyoderma gangrenosum - Acute-onset disease characterized by Pyoderma, acute arthritis, Pyoderma gangrenosum, and Acan.

Demographics

Most common in people aged 25-54
No racial or ethnic predilection
No gender predominance
Incidence difficult to determine, because of rarity of the disease

Diagnosis

Rule by exclusion (See differential in Table 2)
No allergy screen depending on type of PG, but most commonly shows immune-mediated inflammation, hypersensitivity, and T-lymphocyte response. Biopsy usually reveals ulcer extending into dermis.

Management

Systemic treatment for patient with PG with local systemic therapies, depending on extent of disease Local therapy consists of injection into the lesion. Best outcome report used 1-trimethoprim-sulfamethoxazole. Other local treatments reported: heparin, sodium hyaluronate, topical 5-aminosalicylic acid, topical sodium cromoglycate, topical nitroglycerin, and topical corticosteroids on transformed pustules Systemic therapy most commonly consists of prednisone therapy, 40-120 mg/day until ulcer is completely resolved, followed by tapering of therapy. A therapy has also been used. Other systemic agents reported to be successful include cyclosporine, azathioprine, methotrexate, and plasmapheresis with cyclophosphamide. A combination is recommended because of the pathologic nature.




Table 1

Diseases Associated with Pyoderma Gangrenosum

- A. Infectious bacterial disease (eg, STI)
- B. Actinic (premalignant) or basaloid carcinoma
- C. Hematoma (eg, lung, liver)
- D. Hematologic malignancy (leukemia, lymphoma, myelodysplasia, multiple myeloma)
- E. HIV
- F. Adenocarcinoma
- G. Sarcoma

Differential Diagnosis of PG-like Lesions

- A. Infectious process
- B. Angioma
- C. Vasculitis
- D. Ulcer/ultra
- E. Vasculopathy
- F. Polyarteritis
- G. Arteriosclerosis obliterans
- H. Scurvy/ulcers
- I. Pyoderma gangrenosum

Case

Chief Complaint

Patient is a previously healthy 22-year-old male presenting with a 2-month history of progressively spreading ulcer on his leg.

History of Present Illness

Two weeks prior to the onset of the ulcer, patient reported to fall after resulting in a small abrasion. He recalls no other trauma to his leg. The site of injury became tender and developed a green and white ulcer. The ulcer continued to grow over several weeks to form a crusty yellow substance. Patient recalls no fever, malaise, myalgia or arthralgia. Patient reports no other symptoms.

Physical Exam

Patient's vital signs were within normal limits, with temperature 37.2°C and heart rate 100 bpm. There was a 2 cm ulcer on the left leg with a central area of necrosis and a 5 cm area of erythema surrounding the ulcer.

Management

The patient had received several courses of antibiotics as an outpatient including cephalexin, trimethoprim-sulfamethoxazole, and rifampin oral. The ulcer did not improve. He was admitted to the hospital, where he underwent two surgical debridements. Culture were obtained for HSV and fungi, but came back negative. He was treated with 100 mg prednisone daily, but came back with the ulcer again. He was treated with 100 mg prednisone daily. The patient showed no improvement. In this case, a presumptive diagnosis of PG was made, which was confirmed through an outpatient dermatology consult. The patient was treated with 40 mg prednisone daily, and showed impressive improvement within 9 weeks. Physical therapy (physical) was also used to aid in the healing of the ulcer and were able able to minimize the patient's pain. Insulin pump medication was necessary. The patient was scheduled for a follow-up, but was subsequently lost to follow-up.

Conclusion

Our patient's diagnosis was made based on clinical presentation. When biopsy was performed, which did not reveal a diagnosis but was important to exclude other possibilities. Ideally, the patient would have undergone a laboratory because of the high incidence of PG in patients with PG, but laboratory tests have been reported in the patient, the clinical picture may have been clear.

Our case well illustrates the difficulty PG can present a disease. The long differential diagnosis for ulcer of this sort can lead to a long treatment which actually exacerbates the disease. Familiarity with PG is important because the clinical picture can be very confusing. With a sufficient grasp of the disease and its management, a physician will be well prepared to treat and manage this challenging disease.